NFL Biosciences SA
ALNFL
Company Profile
Business description
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Contact
199 rue Helene Boucher
Castelnau-le-Lez34170
FRAT: +33 411937667
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 45.00 | -0.48% |
| CAC 40 | 7,969.69 | 31.40 | 0.40% |
| DAX 40 | 24,363.09 | 69.75 | 0.29% |
| Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,888.01 | 783.40 | 3.12% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,807.82 | 197.65 | 0.46% |
| NZX 50 Index | 13,079.50 | 114.57 | -0.87% |
| S&P 500 | 6,466.91 | 96.74 | 1.52% |
| S&P/ASX 200 | 8,972.40 | 52.00 | -0.58% |
| SSE Composite Index | 3,873.85 | 48.09 | 1.26% |